Ahmed Aribi

2.4k total citations
50 papers, 923 citations indexed

About

Ahmed Aribi is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ahmed Aribi has authored 50 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 17 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Ahmed Aribi's work include Acute Myeloid Leukemia Research (23 papers), CAR-T cell therapy research (11 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Ahmed Aribi is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), CAR-T cell therapy research (11 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Ahmed Aribi collaborates with scholars based in United States, Spain and Italy. Ahmed Aribi's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Janet L. Stringer, Jianqin Shan, Jan Davisson, Guillermo Garcia‐Manero, Stefan Faderl, Stephen J. Forman and Ryotaro Nakamura and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ahmed Aribi

46 papers receiving 912 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ahmed Aribi United States 17 460 382 211 202 132 50 923
Françoise Durrieu France 15 226 0.5× 597 1.6× 186 0.9× 135 0.7× 96 0.7× 28 1.1k
Fiona C. Brown Australia 13 260 0.6× 470 1.2× 143 0.7× 99 0.5× 74 0.6× 27 697
K. O. Kliche United States 10 150 0.3× 266 0.7× 282 1.3× 130 0.6× 54 0.4× 11 912
Marina Lanciotti Italy 17 160 0.3× 267 0.7× 129 0.6× 68 0.3× 84 0.6× 51 733
Ivan Bilić Austria 17 134 0.3× 572 1.5× 256 1.2× 88 0.4× 71 0.5× 33 1.4k
Silke Lüschen Germany 10 438 1.0× 249 0.7× 172 0.8× 74 0.4× 514 3.9× 12 892
N. J. Philpott United Kingdom 10 236 0.5× 339 0.9× 119 0.6× 75 0.4× 40 0.3× 14 703
Dominic Wall Australia 16 130 0.3× 316 0.8× 340 1.6× 67 0.3× 39 0.3× 39 729
Rita Bisogni Italy 14 84 0.2× 502 1.3× 192 0.9× 56 0.3× 59 0.4× 25 868
Guy Cornu Belgium 12 133 0.3× 217 0.6× 66 0.3× 111 0.5× 80 0.6× 38 644

Countries citing papers authored by Ahmed Aribi

Since Specialization
Citations

This map shows the geographic impact of Ahmed Aribi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed Aribi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed Aribi more than expected).

Fields of papers citing papers by Ahmed Aribi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmed Aribi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed Aribi. The network helps show where Ahmed Aribi may publish in the future.

Co-authorship network of co-authors of Ahmed Aribi

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed Aribi. A scholar is included among the top collaborators of Ahmed Aribi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed Aribi. Ahmed Aribi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ngo, Dat, Shanpeng Li, Joycelynne Palmer, et al.. (2024). Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib. Leukemia & lymphoma. 65(3). 372–377. 2 indexed citations
3.
Zhang, Jianying, Vinod Pullarkat, Vaibhav Agrawal, et al.. (2024). Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer. British Journal of Haematology. 205(1). 158–165. 1 indexed citations
4.
Stein, Anthony S., Jianying Zhang, Lucy Ghoda, et al.. (2024). Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 4264–4264. 1 indexed citations
5.
Salhotra, Amandeep, Dongyun Yang, Sally Mokhtari, et al.. (2024). Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT). Transplantation and Cellular Therapy. 30(2). S282–S283. 1 indexed citations
6.
Ong, Shin Yeu, Matthew Mei, Leslie Popplewell, et al.. (2023). Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma. American Journal of Hematology. 98(11). 1751–1761. 17 indexed citations
7.
8.
Malki, Monzr M. Al, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2022). Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances. 6(14). 4098–4106. 15 indexed citations
9.
Ali, Haris, Dat Ngo, Ahmed Aribi, et al.. (2021). Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplantation and Cellular Therapy. 27(11). 938.e1–938.e6. 40 indexed citations
10.
Ball, Brian, Shukaib Arslan, Paul Koller, et al.. (2021). Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. Blood. 138(Supplement 1). 3430–3430. 1 indexed citations
11.
Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations
12.
Salhotra, Amandeep, Dongyun Yang, Sally Mokhtari, et al.. (2020). Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 26(6). 1084–1090. 15 indexed citations
13.
Sandhu, Karamjeet, Sanjeet Dadwal, Dongyun Yang, et al.. (2020). Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 26(12). e322–e327. 29 indexed citations
14.
Aribi, Ahmed, Hagop M. Kantarjian, Charles Koller, et al.. (2008). The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 113(6). 1338–1343. 10 indexed citations
15.
Aribi, Ahmed, Hagop M. Kantarjian, Elihu H. Estey, et al.. (2007). Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 109(7). 1355–1359. 69 indexed citations
16.
Aribi, Ahmed, Gautam Borthakur, Farhad Ravandi, et al.. (2007). Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 109(4). 713–717. 86 indexed citations
17.
Aribi, Ahmed, Yang O. Huh, Michael A. Keating, et al.. (2006). T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leukemia Research. 31(7). 939–945. 27 indexed citations
18.
Aribi, Ahmed, et al.. (2006). Loss of RAB25 expression in breast cancer. International Journal of Cancer. 118(12). 2957–2964. 64 indexed citations
19.
Quintás‐Cardama, Alfonso, Ahmed Aribi, Jörge E. Cortes, et al.. (2006). Novel approaches in the treatment of systemic mastocytosis. Cancer. 107(7). 1429–1439. 29 indexed citations
20.
Aribi, Ahmed & Janet L. Stringer. (2002). Effects of antiepileptic drugs on extracellular pH regulation in the hippocampal CA1 region in vivo. Epilepsy Research. 49(2). 143–151. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Françoise Durrieu Breakdown of academic impact, for papers by Fiona C. Brown Breakdown of academic impact, for papers by K. O. Kliche Breakdown of academic impact, for papers by Marina Lanciotti Breakdown of academic impact, for papers by Ivan Bilić Breakdown of academic impact, for papers by Silke Lüschen Breakdown of academic impact, for papers by N. J. Philpott Breakdown of academic impact, for papers by Dominic Wall Breakdown of academic impact, for papers by Rita Bisogni Breakdown of academic impact, for papers by Guy Cornu
Rankless by CCL
2026